NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of NextCure (NASDAQ:NXTC) in a report released on Friday, Benzinga reports. The brokerage currently has a $8.00 price target on the stock.

Separately, Needham & Company LLC reiterated a buy rating and set a $4.00 price target on shares of NextCure in a research note on Wednesday, March 20th.

NextCure Stock Up 2.7 %

NextCure stock traded up $0.04 during mid-day trading on Friday, reaching $1.53. The company had a trading volume of 108,827 shares, compared to its average volume of 147,942. The firm has a market cap of $42.79 million, a price-to-earnings ratio of -0.67 and a beta of 0.54. The company has a 50 day moving average of $1.72 and a 200-day moving average of $1.40. NextCure has a 52 week low of $0.98 and a 52 week high of $2.57.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.02. On average, analysts predict that NextCure will post -1.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Marquette Asset Management LLC bought a new position in NextCure during the 4th quarter valued at about $66,000. Acuitas Investments LLC raised its position in NextCure by 30.0% in the 4th quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock valued at $425,000 after purchasing an additional 85,982 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in NextCure in the first quarter worth $952,000. Finally, Cable Car Capital LLC bought a new stake in shares of NextCure during the fourth quarter worth $702,000. 42.65% of the stock is owned by institutional investors.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.